Comments
Loading...

Neurocrine Biosciences Analyst Ratings

NBIXNASDAQ
Logo brought to you by Benzinga Data
$120.18
1.060.89%
At close: -
$123.04
2.862.38%
After Hours: 4:14 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$219.00
Lowest Price Target1
$115.00
Consensus Price Target1
$160.28

Neurocrine Biosciences Analyst Ratings and Price Targets | NASDAQ:NBIX | Benzinga

Neurocrine Biosciences Inc has a consensus price target of $160.28 based on the ratings of 25 analysts. The high is $219 issued by Oppenheimer on August 2, 2024. The low is $115 issued by BMO Capital on May 6, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, RBC Capital, and Guggenheim on May 6, 2025, respectively. With an average price target of $154.67 between Piper Sandler, RBC Capital, and Guggenheim, there's an implied 25.70% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
9
Feb
2
Mar
6
Apr
6
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
RBC Capital
Guggenheim
BMO Capital
UBS

1calculated from analyst ratings

Analyst Ratings for Neurocrine Biosciences

Buy NowGet Alert
05/06/2025Buy Now25.16%Piper Sandler
David Amsellem77%
$160 → $154ReiteratesOverweight → OverweightGet Alert
05/06/2025Buy Now17.85%RBC Capital
Brian Abrahams49%
$137 → $145MaintainsOutperformGet Alert
05/06/2025Buy Now34.1%Guggenheim
Yatin Suneja51%
$155 → $165MaintainsBuyGet Alert
05/06/2025Buy Now-6.53%BMO Capital
Evan Seigerman63%
$96 → $115MaintainsMarket PerformGet Alert
05/06/2025Buy Now23.54%UBS
Ashwani Verma48%
$137 → $152MaintainsBuyGet Alert
05/06/2025Buy Now30.04%Canaccord Genuity
Sumant Kulkarni42%
$158 → $160MaintainsBuyGet Alert
05/06/2025Buy Now12.97%Needham
Ami Fadia56%
$138 → $139MaintainsBuyGet Alert
04/28/2025Buy Now28.41%Canaccord Genuity
Sumant Kulkarni42%
$163 → $158MaintainsBuyGet Alert
04/24/2025Buy Now50.36%Evercore ISI Group
Cory Kasimov68%
$190 → $185MaintainsOutperformGet Alert
04/22/2025Buy Now36.54%HC Wainwright & Co.
Andrew Fein56%
$185 → $168MaintainsBuyGet Alert
04/15/2025Buy Now12.16%Needham
Ami Fadia56%
→ $138UpgradeHold → BuyGet Alert
04/14/2025Buy Now11.35%RBC Capital
Brian Abrahams49%
$138 → $137UpgradeSector Perform → OutperformGet Alert
04/04/2025Buy Now11.35%UBS
Ashwani Verma48%
$154 → $137MaintainsBuyGet Alert
03/26/2025Buy Now49.54%JP Morgan
Anupam Rama57%
$183 → $184MaintainsOverweightGet Alert
03/07/2025Buy Now21.91%Morgan Stanley
Jeffrey Hung51%
$185 → $150Assumes → OverweightGet Alert
02/24/2025Buy Now50.36%HC Wainwright & Co.
Andrew Fein56%
$185 → $185ReiteratesBuy → BuyGet Alert
02/21/2025Buy Now50.36%HC Wainwright & Co.
Andrew Fein56%
$185 → $185ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now32.48%Guggenheim
Yatin Suneja51%
$165 → $163MaintainsBuyGet Alert
02/10/2025Buy Now50.36%HC Wainwright & Co.
Andrew Fein56%
$190 → $185MaintainsBuyGet Alert
02/07/2025Buy Now20.29%RBC Capital
Brian Abrahams49%
$154 → $148MaintainsSector PerformGet Alert
02/07/2025Buy Now19.47%Wedbush
Laura Chico46%
$157 → $147MaintainsOutperformGet Alert
02/07/2025Buy Now32.48%Canaccord Genuity
Sumant Kulkarni42%
$172 → $163MaintainsBuyGet Alert
02/07/2025Buy Now50.36%HC Wainwright & Co.
Andrew Fein56%
$190 → $185MaintainsBuyGet Alert
02/07/2025Buy Now—Needham
Ami Fadia56%
—ReiteratesHold → HoldGet Alert
02/07/2025Buy Now45.48%B of A Securities
Tazeen Ahmad55%
$184 → $179MaintainsBuyGet Alert
02/04/2025Buy Now50.36%Morgan Stanley
Jeffrey Hung51%
$170 → $185MaintainsOverweightGet Alert
01/30/2025Buy Now43.04%UBS
Ashwani Verma48%
$162 → $176MaintainsBuyGet Alert
01/08/2025Buy Now31.66%UBS
Ashwani Verma48%
$142 → $162MaintainsBuyGet Alert
12/23/2024Buy Now30.04%Piper Sandler
David Amsellem77%
$160 → $160ReiteratesOverweight → OverweightGet Alert
12/23/2024Buy Now34.1%Barclays
Carter Gould57%
$160 → $165MaintainsOverweightGet Alert
12/20/2024Buy Now—Needham
Ami Fadia56%
—ReiteratesHold → HoldGet Alert
12/16/2024Buy Now20.29%Wedbush
Laura Chico46%
$148 → $148ReiteratesOutperform → OutperformGet Alert
12/16/2024Buy Now54.42%HC Wainwright & Co.
Andrew Fein56%
$190 → $190ReiteratesBuy → BuyGet Alert
11/11/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
11/01/2024Buy Now54.42%HC Wainwright & Co.
Andrew Fein56%
$190 → $190ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/30/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/29/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/17/2024Buy Now-7.35%BMO Capital
Evan Seigerman63%
$128 → $114MaintainsMarket PerformGet Alert
10/10/2024Buy Now25.98%Raymond James
Danielle Brill44%
→ $155Reinstates → OutperformGet Alert
10/08/2024Buy Now8.09%RBC Capital
Brian Abrahams49%
$133 → $133ReiteratesSector Perform → Sector PerformGet Alert
10/04/2024Buy Now8.09%RBC Capital
Brian Abrahams49%
$136 → $133MaintainsSector PerformGet Alert
09/16/2024Buy Now25.98%Cantor Fitzgerald
Charles Duncan69%
$155 → $155ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now30.04%Barclays
Carter Gould57%
$180 → $160MaintainsOverweightGet Alert
08/29/2024Buy Now25.98%Cantor Fitzgerald
Charles Duncan69%
$170 → $155MaintainsOverweightGet Alert
08/29/2024Buy Now4.03%BMO Capital
Evan Seigerman63%
$142 → $128MaintainsMarket PerformGet Alert
08/29/2024Buy Now29.23%Piper Sandler
David Amsellem77%
$131 → $159UpgradeNeutral → OverweightGet Alert
08/29/2024Buy Now10.53%RBC Capital
Brian Abrahams49%
$143 → $136MaintainsSector PerformGet Alert
08/29/2024Buy Now54.42%HC Wainwright & Co.
Andrew Fein56%
$190 → $190ReiteratesBuy → BuyGet Alert
08/29/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
08/19/2024Buy Now53.61%Jefferies
Akash Tewari41%
$177 → $189MaintainsBuyGet Alert
08/07/2024Buy Now47.11%JP Morgan
Anupam Rama57%
$173 → $181MaintainsOverweightGet Alert
08/05/2024Buy Now54.42%HC Wainwright & Co.
Andrew Fein56%
$160 → $190MaintainsBuyGet Alert
08/02/2024Buy Now16.22%RBC Capital
Brian Abrahams49%
$136 → $143MaintainsSector PerformGet Alert
08/02/2024Buy Now46.29%Guggenheim
Yatin Suneja51%
$170 → $180MaintainsBuyGet Alert
08/02/2024Buy Now28.41%Citigroup
David Hoang42%
$150 → $158MaintainsNeutralGet Alert
08/02/2024Buy Now77.99%Oppenheimer
Jay Olson60%
$216 → $219MaintainsOutperformGet Alert
08/02/2024Buy Now46.29%Barclays
Carter Gould57%
$169 → $180MaintainsOverweightGet Alert
08/02/2024Buy Now46.29%Baird
Brian Skorney57%
$157 → $180MaintainsOutperformGet Alert
08/01/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
07/25/2024Buy Now25.98%Cantor Fitzgerald
Charles Duncan69%
$155 → $155ReiteratesOverweight → OverweightGet Alert
07/25/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
07/12/2024Buy Now38.17%Morgan Stanley
Jeffrey Hung51%
$160 → $170MaintainsOverweightGet Alert
07/10/2024Buy Now40.6%JP Morgan
Anupam Rama57%
$169 → $173MaintainsOverweightGet Alert
06/12/2024Buy Now30.04%Morgan Stanley
Jeffrey Hung51%
$160 → $160MaintainsOverweightGet Alert
05/29/2024Buy Now23.54%Wedbush
Laura Chico46%
$152 → $152ReiteratesOutperform → OutperformGet Alert
05/28/2024Buy Now56.86%UBS
Ashwani Verma48%
$174 → $193MaintainsBuyGet Alert
05/14/2024Buy Now42.23%Evercore ISI Group
Cory Kasimov68%
→ $175Initiates → OutperformGet Alert
05/03/2024Buy Now21.91%Citigroup
David Hoang42%
$140 → $150MaintainsNeutralGet Alert
05/02/2024Buy Now33.29%Canaccord Genuity
Sumant Kulkarni42%
$154 → $164MaintainsBuyGet Alert
05/02/2024Buy Now38.17%Guggenheim
Yatin Suneja51%
$164 → $170MaintainsBuyGet Alert
05/02/2024Buy Now37.35%Barclays
Carter Gould57%
$150 → $169MaintainsOverweightGet Alert
05/02/2024Buy Now12.16%BMO Capital
Evan Seigerman63%
$129 → $138MaintainsMarket PerformGet Alert
05/02/2024Buy Now75.55%Oppenheimer
Jay Olson60%
$200 → $216MaintainsOutperformGet Alert
05/02/2024Buy Now30.04%HC Wainwright & Co.
Andrew Fein56%
$150 → $160MaintainsBuyGet Alert
05/02/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
05/01/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
04/24/2024Buy Now21.91%HC Wainwright & Co.
Andrew Fein56%
$150 → $150ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now38.17%Wells Fargo
Mohit Bansal67%
$140 → $170UpgradeEqual-Weight → OverweightGet Alert
04/24/2024Buy Now62.55%Oppenheimer
Jay Olson60%
$200 → $200MaintainsOutperformGet Alert
04/23/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
04/17/2024Buy Now19.47%Wedbush
Laura Chico46%
$147 → $147ReiteratesOutperform → OutperformGet Alert
04/10/2024Buy Now25.98%Cantor Fitzgerald
Charles Duncan69%
→ $155ReiteratesOverweight → OverweightGet Alert
03/20/2024Buy Now28.41%JP Morgan
Anupam Rama57%
$148 → $158MaintainsOverweightGet Alert
03/13/2024Buy Now62.55%Oppenheimer
Jay Olson60%
$170 → $200MaintainsOutperformGet Alert
02/23/2024Buy Now20.29%JP Morgan
Anupam Rama57%
$154 → $148MaintainsOverweightGet Alert
02/08/2024Buy Now13.78%Citigroup
David Hoang42%
$141 → $140MaintainsNeutralGet Alert
02/08/2024Buy Now13.78%Mizuho
Uy Ear64%
$116 → $140MaintainsNeutralGet Alert
02/08/2024Buy Now13.78%Wells Fargo
Mohit Bansal67%
$127 → $140MaintainsEqual-WeightGet Alert
01/25/2024Buy Now24.35%Goldman Sachs
Chris Shibutani55%
$134 → $153MaintainsBuyGet Alert
01/23/2024Buy Now21.91%Barclays
Carter Gould57%
$145 → $150MaintainsOverweightGet Alert
12/18/2023Buy Now17.04%Stifel
Paul Matteis44%
$141 → $144MaintainsBuyGet Alert
12/13/2023Buy Now3.22%Wells Fargo
Mohit Bansal67%
$110 → $127MaintainsEqual-WeightGet Alert
12/13/2023Buy Now3.22%Citigroup
David Hoang42%
→ $127Initiates → NeutralGet Alert
12/12/2023Buy Now10.53%Deutsche Bank
Neena Bitritto-Garg58%
→ $136Initiates → BuyGet Alert
12/07/2023Buy Now21.91%Canaccord Genuity
Sumant Kulkarni42%
→ $150ReiteratesBuy → BuyGet Alert
11/10/2023Buy Now-18.73%BMO Capital
Evan Seigerman63%
$111 → $100MaintainsMarket PerformGet Alert
11/10/2023Buy Now-1.66%RBC Capital
Brian Abrahams49%
$128 → $121MaintainsSector PerformGet Alert
11/10/2023Buy Now-7.35%Mizuho
Uy Ear64%
$116 → $114MaintainsNeutralGet Alert
11/03/2023Buy Now-5.72%Mizuho
Uy Ear64%
$113 → $116MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Neurocrine Biosciences (NBIX) stock?

A

The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $154.00 expecting NBIX to rise to within 12 months (a possible 25.16% upside). 67 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?

A

The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Piper Sandler, and Neurocrine Biosciences reiterated their overweight rating.

Q

When was the last upgrade for Neurocrine Biosciences (NBIX)?

A

The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.

Q

When was the last downgrade for Neurocrine Biosciences (NBIX)?

A

There is no last downgrade for Neurocrine Biosciences.

Q

When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?

A

While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a reiterated with a price target of $160.00 to $154.00. The current price Neurocrine Biosciences (NBIX) is trading at is $123.04, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch